ETVAX VACCINE

About:

• Enterotoxigenic E. coli (ETEC) bacteria are a primary cause of diarrhea, leading to substantial illness and death in children in low- and middle-income countries (LMICs). Currently there is no ETEC vaccine available on the market for use in children in ETEC high-risk areas.
  
  
• Now, an oral ETEC vaccine candidate, named ETVAX, was developed at University of Gothenburg in collaboration with Scandinavian Biopharma, Stockholm.
  
  
• ETVAX consists of inactivated E. coli bacteria expressing high levels of protective antigens and the ETEC-based B subunit protein LCTBA.
  
  
• Science journal, The Lancet, reports that it has been proved safe and effective in an early-stage clinical trial in Bangladesh against enterotoxigenic E. coli diarrhea in children from 6 months to 5 years of age.